BTIG analyst David Larsen maintained a Buy rating on Evolent Health (NYSE:EVH) on Friday, setting a price target of $30, which is approximately 14.55% above the present share price of $26.19.
Larsen expects Evolent Health to post earnings per share (EPS) of -$0.11 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Evolent Health, with an average price target of $29.
The analysts price targets range from a high of $32 to a low of $26.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $222.06 million and a net profit of -$7.67 million. The company's market cap is $2.29 billion.
According to TipRanks.com, BTIG analyst David Larsen is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.5% and a 41.72% success rate.
Evolent Health, Inc. engages in the provision of health care delivery and payment services. Its solutions include population health management, health plan administration and third party administration, network performance management, risk adjustment, pharmacy benefit management, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services segment and True Health segment. The Services segment includes three types of services designed to help partners manage patient health; value-based care services, specialty care management services and comprehensive health plan administration services. The True Health segment, which operates a health plan in New Mexico, and provides reinsurance to NMHC, takes on certain insurance and underwriting costs in pricing its premiums. The company was founded by Frank J. Williams, Seth B. Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.